MTARC1 p.A165 ablation reduces hepatocellular carcinoma aggressiveness in vitro and in vivo
Downregulation of MTARC1 p.A165 inhibits lipid accumulation, dampens tumor-promoting pathways and restricts tumor growth, highlighting MTARC1 as a promising therapeutic target for HCC.
Authors
- Xiangdong Gongye (ORCID: https://orcid.org/0009-0001-1267-1835)
- Bernice Asiedu (ORCID: https://orcid.org/0000-0001-6407-7566)
- J Zhang
- Lohitesh Kovooru
- Emelie Barreby (ORCID: https://orcid.org/0000-0002-6467-5280)
- Rosellina Margherita Mancina (ORCID: https://orcid.org/0000-0002-1126-3071)
- Margit Mahlapuu
- Tanmoy Dutta (ORCID: https://orcid.org/0000-0003-2816-2899)
- Stefano Romeo
- Patrizia Infelise
- Francesco Giuseppe Monni
- Oveis Jamialahmadi
Institutions
- Karolinska University Hospital (SE)
- Università Campus Bio-Medico (IT)
- Sahlgrenska University Hospital (SE)
- Karolinska Institutet (SE)
- Magna Graecia University (IT)
- Integrated Cardio Metabolic Centre (SE)
- Istituto di Fisiologia Clinica (IT)
- National Research Council (IT)
- Link Campus University (IT)
- University of Gothenburg (SE)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3350/cmh.2025.1261
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancerfonden
- Karolinska Institutet
- Novo Nordisk
- Vetenskapsrådet
- Science for Life Laboratory
- Novo Nordisk Fonden
- Sahlgrenska Akademin
- Wallenberg Centre for Molecular and Translational Medicine